Variable | Progression-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
P value | HR (95 % CI) | P value | P value | HR (95 % CI) | P value | |
Gender (female vs. male) | 0.025 | 0.010 | ||||
Age (>60 vs. ≤60 years) | 0.660 | 0.887 | ||||
ECOG score (≥2 vs. 0–1) | 0.124 | 0.015 | ||||
Stage (II vs. I) | 0.001 | 3.06 (1.30–7.22) | 0.010 | 0.003 | 4.49 (1.34–15.02) | 0.015 |
B symptoms (yes vs. no) | 0.251 | 0.264 | ||||
LDH (elevated vs. normal) | 0.020 | 0.001 | ||||
IPI (2 vs. 0–1) | 0.006 | 0.001 | 3.29 (1.13–9.57) | 0.029 | ||
NKPI (2–3 vs. 0–1) | 0.095 | 0.058 | ||||
Chemotherapy (GELOX vs. CHOP-L) | 0.661 | 0.800 | ||||
Treatment response (non-CR vs. CR) | 0.001 | 3.50 (1.53–8.01) | 0.003 | 0.001 | 5.99 (1.89–18.98) | 0.002 |
Serum PD-L1 (≥3.4 vs. <3.4 ng/ml) | <0.001 | 4.98 (2.22–11.21) | <0.001 | <0.001 | 6.76 (2.12–21.59) | 0.001 |